Phase 3 · NCT06662383
TRIUMPH-5
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- TRIUMPH-5
- ClinicalTrials.gov ID
- NCT06662383
- Indication
- Obesity
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 800
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Tirzepatide
- Comparator
- Not reported
- Eligible ages
- 18 Years – No maximum
- Locations
- 65 sites · Argentina, Germany, Poland, Puerto Rico, United States
- Study start
- 1 Nov 2024
- Primary completion
- 1 Nov 2026
- Study completion
- 1 Dec 2026
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 20 Jul 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Body Mass Index (BMI); Change from Baseline in Waist Circumference; Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Change from Baseline in Hemoglobin A1c (HbA1c); Percent Change from Baseline in Fasting Insulin; Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)
Registry monitoring
Latest Trial Changes
| Field | Change | Detected | Source |
|---|---|---|---|
| Recruitment status | Recruiting→Active, not recruiting | 4 Sept 2026 | ClinicalTrials.gov |
| Enrolment | 760→800 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary completion date | 2027-12-31→2026-11-01 | 4 Sept 2026 | ClinicalTrials.gov |
| Study completion date | Not yet confirmed→2026-12-01 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary endpoints | Not yet confirmed→Percent Change from Baseline in Body Weight | 4 Sept 2026 | ClinicalTrials.gov |